Immunocore (IMCR) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic priorities and platform overview

• Focused on expanding KIMMTRAK in melanoma, advancing into new tumor types, and unlocking value beyond oncology, including infectious and autoimmune diseases.

• The modular TCR bispecific platform enables both immune activation for cancer/infection and immune down-modulation for autoimmunity.

• Major data catalysts expected in 2026, with ongoing execution in 2025 and further milestones through 2028.

KIMMTRAK performance and growth plans

• Achieved 70–90% market penetration in major regions, with 30% revenue growth and 14 consecutive quarters of growth.

• Five-year overall survival data to be published in H1 2026; continued US and global expansion targeted.

• Two phase III trials underway: TEBE-AM (cutaneous melanoma) and adjuvant uveal melanoma, aiming to expand eligible patients from 1,000 to 6,000.

• TEBE-AM enrollment to complete in H1 2026, with data possible in H2 2026.

• ADAM trial for adjuvant uveal melanoma started in late 2024, with accrual expected to finish by end of 2027 or early 2028.

Pipeline expansion: PRAME and beyond

• PRAME phase III (PRISM-MEL) in first-line cutaneous melanoma progressing, with enrollment completion targeted for 2027.

• PRAME also being explored in ovarian and non-small cell lung cancer, with key data readouts expected in H2 2026.

• PRAME half-life extension in clinic since late 2024, with ongoing dose escalation and data anticipated in 2026.

• PIWIL1, a novel target for colorectal and GI cancers, in dose escalation since December 2024; initial data expected in 2025 or 2027.